Clinical Application of a Hybrid RapidArc Radiotherapy Technique for Locally Advanced Lung Cancer.
Radiation treatment planning for locally advanced lung cancer can be technically challenging, as delivery of ≥60 Gy to large volumes with concurrent chemotherapy is often associated with significant risk of normal tissue toxicity. We clinically implemented a novel hybrid RapidArc technique in patients with lung cancer and compared these plans with 3-dimensional conformal radiotherapy and RapidArc-only plans.



Hybrid RapidArc was used to treat 11 patients with locally advanced lung cancer having bulky mediastinal adenopathy. All 11 patients received concurrent chemotherapy. All underwent a 4-dimensional computed tomography planning scan. Hybrid RapidArc plans concurrently combined static (60%) and RapidArc (40%) beams. All cases were replanned using 3- to 5-field 3-dimensional conformal radiotherapy and RapidArc technique as controls.



Significant reductions in dose were observed in hybrid RapidArc plans compared to 3-dimensional conformal radiotherapy plans for total lung V20 and mean (-2% and -0.6 Gy); contralateral lung mean (-2.92 Gy); and esophagus V60 and mean (-16.0% and -2.2 Gy; all P < .05). Contralateral lung doses were significantly lower for hybrid RapidArc plans compared to RapidArc-only plans (all P < .05). Compared to 3-dimensional conformal radiotherapy, heart V60 and mean dose were significantly improved with hybrid RapidArc (3% vs 5%, P = .04 and 16.32 Gy vs 16.65 Gy, P = .03). However, heart V40 and V45 and maximum spinal cord dose were significantly lower with RapidArc plans compared to hybrid RapidArc plans. Conformity and homogeneity were significantly better with hybrid RapidArc plans compared to 3-dimensional conformal radiotherapy plans ( P < .05). Treatment was well tolerated, with no grade 3+ toxicities.



To our knowledge, this is the first report on the clinical application of hybrid RapidArc in patients with locally advanced lung cancer. Hybrid RapidArc permitted safe delivery of 60 to 66 Gy to large lung tumors with concurrent chemotherapy and demonstrated advantages for reduction in low-dose lung volumes, esophageal dose, and mean heart dose.
1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Scott R
SR
Silva
1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Murat
M
Surucu
1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Jennifer
J
Steber
1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Matthew M
MM
Harkenrider
1 Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Mehee
M
Choi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D056973:Four-Dimensional Computed Tomography; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011874:Radiometry; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000009:adverse effects / Q000379:methods; D061089:Radiotherapy, Image-Guided; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome; D047368:Tumor Burden
3D conformal radiotherapy; hybrid RapidArc; locally advanced lung cancer; radiation esophagitis; radiation pneumonitis; radiation toxicity
Med Phys. 2008 Jan;35(1):310-7
18293586
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1408-18
18262730
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1455-9
18243570
Clin Oncol (R Coll Radiol). 2014 Feb;26(2):67-80
24290238
Acta Oncol. 2015 Mar;54(3):427-32
25383450
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50
22682812
Cancer Treat Rev. 2010 Aug;36(5):393-9
20181430
Med Dosim. 2013 Winter;38(4):460-6
24094572
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):608-16
20100639
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407
16997503
Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):845-6
8690655
Radiother Oncol. 2011 Nov;101(2):298-302
21907438
Med Phys. 2010 Mar;37(3):1350-9
20384272
PLoS One. 2016 Apr 21;11(4):e0151988
27100968
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
2032882
Med Phys. 2006 May;33(5):1380-7
16752574
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1231-9
8262852
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):690-6
24035329
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
20171502
Nat Rev Cancer. 2004 Sep;4(9):737-47
15343280
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1260-9
16798418
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):175-82
25863764
Pract Radiat Oncol. 2016 Nov - Dec;6(6):388-394
27025161
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e297-303
22579380
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5
16751058